Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alexion Pharmaceuticals Inc. ALXN

Healthcare Biotechnology
Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Next-generation Ultomiris is approved in PNH and aHUS... see more

Recent & Breaking News (NDAQ:ALXN)

Alexion to Present at the Barclays Global Healthcare Conference

Business Wire March 5, 2013

Alexion Joins Eurordis, NORD and Patient Organizations Worldwide in Celebrating Rare Disease Day 2013

Business Wire February 28, 2013

Alexion to Present at the Cowen and Company 33rd Annual Health Care Conference

Business Wire February 25, 2013

Turn Timing Into Profits With XOM, CF, OC and ALXN

Marketwired February 21, 2013

StockCall Scrutinizes Alexion Pharma and Celgene: Biotech Stocks Offers Healthy Returns

PR Newswire February 19, 2013

Alexion Reports Fourth Quarter and Full Year 2012 Results

Business Wire February 14, 2013

Alexion Recommends Rejection of Mini-Tender Offer by TRC Capital Corporation

Business Wire February 7, 2013

Free Research Report on Amazon.com, Inc., Alexion Pharmaceuticals, Inc., iShares Trust and Accenture plc

Marketwired February 4, 2013

Alexion Pharmaceuticals to Report Fourth Quarter and Full Year 2012 Results on Thursday, February 14, 2013

Business Wire January 31, 2013

Alexion to Present at the JP Morgan 31st Annual Healthcare Conference

Business Wire January 2, 2013

Should Recent Insider Selling on AET, IM, ALXN and AFG Matter to You?

Marketwired December 21, 2012